We aimed to evaluate the clinical efficacy and safety of monoclonal antibodies targeting calcitonin gene‐related peptide (anti‐CGRP) in reducing the symptoms and frequency of migraine in patients diagnosed with CM refractory to BoNT‐A in clinical practice. Here, CALCA is linked to migraine disorder.